Literature DB >> 15143086

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

Arnab Chakravarti1, Gary Zhai, Yoshiyuki Suzuki, Sormeh Sarkesh, Peter M Black, Alona Muzikansky, Jay S Loeffler.   

Abstract

PURPOSE: The objectives of this study were to examine activation patterns of the phosphatidylinositol 3-kinase (PI3K) pathway in gliomas and to examine the prognostic significance of PI3K pathway activation using snap-frozen clinical specimens.
MATERIALS AND METHODS: Levels of expression of PI3K pathway members were assessed in 92 prospectively collected gliomas through quantitative Western analysis using total and phospho-specific antibodies for PI3K, Akt, and p70(s6k). Both expression and expression levels of these PI3K pathway members were correlated with histology, markers of apoptosis (cleaved caspase 3), and with clinical outcome (eg, overall survival).
RESULTS: It was determined that activation of all three PI3K pathway members were significantly more frequent in glioblastoma multiforme than in non-glioblastoma multiforme tumors. Levels of phospho-PI3K, phospho-Akt, and phospho-p70(s6k) were all found to be inversely associated with cleaved caspase 3 levels, suggesting PI3K pathway activation is associated with reduced levels of apoptosis. Perhaps most importantly, activation of PI3K pathway members was found to be significantly associated with reduced survival times when all glioma cases were considered in aggregate. When glioblastoma cases were considered separately, the prognostic value of PI3K activation remained significant, suggesting that PI3K activation may directly be associated with radiation resistance, given that this was the only adjuvant therapy administered to this subset of patients.
CONCLUSION: Activation of the PI3K pathway is significantly associated with increasing tumor grade, decreased levels of apoptosis, and with adverse clinical outcome in human gliomas. Molecular pathways regulating PI3K activation would appear to be promising targets in the clinical management of glioma patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15143086     DOI: 10.1200/JCO.2004.07.193

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  142 in total

1.  A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.

Authors:  Warren P Mason; Mary Macneil; Petr Kavan; Jacob Easaw; David Macdonald; Brian Thiessen; Shweta Urva; Zarnie Lwin; Lynn McIntosh; Elizabeth Eisenhauer
Journal:  Invest New Drugs       Date:  2011-12-09       Impact factor: 3.850

2.  Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells.

Authors:  Shilpa Puli; Aditi Jain; James C K Lai; Alok Bhushan
Journal:  Neurochem Res       Date:  2010-02-23       Impact factor: 3.996

Review 3.  PI3K signaling in glioma--animal models and therapeutic challenges.

Authors:  Christine K Cheng; Qi-Wen Fan; William A Weiss
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

4.  N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.

Authors:  Wolfgang Wick; Susan Dettmer; Anne Berberich; Tobias Kessler; Irini Karapanagiotou-Schenkel; Antje Wick; Frank Winkler; Elke Pfaff; Benedikt Brors; Jürgen Debus; Andreas Unterberg; Martin Bendszus; Christel Herold-Mende; Andreas Eisenmenger; Andreas von Deimling; David T W Jones; Stefan M Pfister; Felix Sahm; Michael Platten
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

5.  Efficacy of rapamycin against glioblastoma cancer stem cells.

Authors:  M Mendiburu-Eliçabe; J Gil-Ranedo; M Izquierdo
Journal:  Clin Transl Oncol       Date:  2013-09-17       Impact factor: 3.405

Review 6.  Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme.

Authors:  Gulten Tuncel; Rasime Kalkan
Journal:  Med Oncol       Date:  2018-08-04       Impact factor: 3.064

7.  The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme.

Authors:  Brittany Aguila; Adina Brett Morris; Raffaella Spina; Eli Bar; Julie Schraner; Robert Vinkler; Jason W Sohn; Scott M Welford
Journal:  Cancer Lett       Date:  2019-08-01       Impact factor: 8.679

Review 8.  Combining drugs and radiotherapy: from the bench to the bedside.

Authors:  Kamalakannan Palanichamy; Arnab Chakravarti
Journal:  Curr Opin Neurol       Date:  2009-12       Impact factor: 5.710

Review 9.  Common corruption of the mTOR signaling network in human tumors.

Authors:  S Menon; B D Manning
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

Review 10.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.